Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study
Abstract Objective To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid. Methods From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospective...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-07-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.924 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849411966958829568 |
|---|---|
| author | Lingyu Hu Ruiting Huang Fuqiong Jiang Shuqiong You Qian Wu |
| author_facet | Lingyu Hu Ruiting Huang Fuqiong Jiang Shuqiong You Qian Wu |
| author_sort | Lingyu Hu |
| collection | DOAJ |
| description | Abstract Objective To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid. Methods From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospectively to analyze the therapeutic effect and changes in laboratory indexes. Results The records of a total of 11 patients with bullous pemphigoid who were treated with dupilumab was reviewed. Within 2 weeks of the treatment, 10 (90.9%) of the 11 patients had complete or substantial control of the disease. The BPDAI scores of the patients decreased from baseline 113 (62, 181) to 37 (6, 130) at 2 weeks (p = .001) and 4 (0, 37) at 12 weeks after treatment (p < .001). In the 11 patients treated with dupilumab, the relief time of pruritus was 0–3 days (0.5, 7) days, and the pruritus was significantly alleviated after 2 weeks (t = 15.925, p < .001). The DLQI score decreased from (25.5 ± 2.5) before treatment, to (11.8 ± 4.4) at 2 weeks (t = 10.764, p < .001) and (2.1 ± 1.9) at 12 weeks (t = 30.038, p < .001). The patients had high eosinophil counts, high serum IgE levels, low serum total protein levels, and abnormal blood coagulation function. The aforementioned indicators gradually returned to normal after treatment. No adverse reactions occurred during the treatment. Conclusion Dupilumab can effectively control the condition of bullous pemphigoid, efficiently relieve pruritus symptoms, and is relatively safe. |
| format | Article |
| id | doaj-art-6064aa7093044cf585a081b3ba01e73c |
| institution | Kabale University |
| issn | 2050-4527 |
| language | English |
| publishDate | 2023-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-6064aa7093044cf585a081b3ba01e73c2025-08-20T03:34:36ZengWileyImmunity, Inflammation and Disease2050-45272023-07-01117n/an/a10.1002/iid3.924Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary studyLingyu Hu0Ruiting Huang1Fuqiong Jiang2Shuqiong You3Qian Wu4Department of Dermatology The Second Affiliated Hospital of Kunming Medical University Kunming Yunnan ChinaDepartment of Dermatology The Second Affiliated Hospital of Kunming Medical University Kunming Yunnan ChinaDepartment of Dermatology The Second Affiliated Hospital of Kunming Medical University Kunming Yunnan ChinaDepartment of Dermatology The Second Affiliated Hospital of Kunming Medical University Kunming Yunnan ChinaDepartment of Dermatology The Second Affiliated Hospital of Kunming Medical University Kunming Yunnan ChinaAbstract Objective To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid. Methods From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospectively to analyze the therapeutic effect and changes in laboratory indexes. Results The records of a total of 11 patients with bullous pemphigoid who were treated with dupilumab was reviewed. Within 2 weeks of the treatment, 10 (90.9%) of the 11 patients had complete or substantial control of the disease. The BPDAI scores of the patients decreased from baseline 113 (62, 181) to 37 (6, 130) at 2 weeks (p = .001) and 4 (0, 37) at 12 weeks after treatment (p < .001). In the 11 patients treated with dupilumab, the relief time of pruritus was 0–3 days (0.5, 7) days, and the pruritus was significantly alleviated after 2 weeks (t = 15.925, p < .001). The DLQI score decreased from (25.5 ± 2.5) before treatment, to (11.8 ± 4.4) at 2 weeks (t = 10.764, p < .001) and (2.1 ± 1.9) at 12 weeks (t = 30.038, p < .001). The patients had high eosinophil counts, high serum IgE levels, low serum total protein levels, and abnormal blood coagulation function. The aforementioned indicators gradually returned to normal after treatment. No adverse reactions occurred during the treatment. Conclusion Dupilumab can effectively control the condition of bullous pemphigoid, efficiently relieve pruritus symptoms, and is relatively safe.https://doi.org/10.1002/iid3.924blood coagulation functiondupilumab biologicseosinophilsIL‐13IL‐4immunoglobulin E |
| spellingShingle | Lingyu Hu Ruiting Huang Fuqiong Jiang Shuqiong You Qian Wu Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study Immunity, Inflammation and Disease blood coagulation function dupilumab biologics eosinophils IL‐13 IL‐4 immunoglobulin E |
| title | Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study |
| title_full | Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study |
| title_fullStr | Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study |
| title_full_unstemmed | Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study |
| title_short | Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study |
| title_sort | concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity a preliminary study |
| topic | blood coagulation function dupilumab biologics eosinophils IL‐13 IL‐4 immunoglobulin E |
| url | https://doi.org/10.1002/iid3.924 |
| work_keys_str_mv | AT lingyuhu concomitantuseofdupilumabwithglucocorticoidinbullouspemphigoidreducesdiseaseseverityapreliminarystudy AT ruitinghuang concomitantuseofdupilumabwithglucocorticoidinbullouspemphigoidreducesdiseaseseverityapreliminarystudy AT fuqiongjiang concomitantuseofdupilumabwithglucocorticoidinbullouspemphigoidreducesdiseaseseverityapreliminarystudy AT shuqiongyou concomitantuseofdupilumabwithglucocorticoidinbullouspemphigoidreducesdiseaseseverityapreliminarystudy AT qianwu concomitantuseofdupilumabwithglucocorticoidinbullouspemphigoidreducesdiseaseseverityapreliminarystudy |